Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Key Decisions in HIV Care: Choosing ART in the Context of Virologic Failure and Resistance

In this on-demand recording of a live webinar, expert faculty review key considerations when choosing ART for patients with virologic failure and resistance, including how to build an optimized background regimen and the data to support the inclusion of novel therapies into ART regimens.
W. David Hardy, MD
Josep M. Llibre, MD, PhD
Released: December 29, 2021

In this episode from the series “Key Decisions in HIV Care,” W. David Hardy, MD, and Josep M. Llibre, MD, PhD, discuss important considerations for ART use in the context of virologic failure and resistance, including:

  • A discussion of the definitions of the following: highly treatment experienced, complex ART, multidrug-resistant HIV, and limited treatment options
  • The scope of the problem, including data from the CNICS cohort
  • DHHS and EACS guideline recommendations on the management of virologic failure and drug resistance, including recommendations for the use of genotypic and phenotypic genotyping and proviral DNA sequencing
  • Construction of an optimized background regimen with discussion of the OPTIONS, DAWNING, NADIA, and VIKING-3 trials
  • Novel treatment options, including ibalizumab and data from TMB-301/-311, fostemsavir and data from BRIGHTE, and lenacapavir and data from CAPELLA

Information on this Educational Activity


W. David Hardy, MD

Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine

Division of Infectious Diseases
Keck School of Medicine of USC
Los Angeles, California

W. David Hardy, MD, has disclosed that he has received consulting fees from Enochian Biosciences, Gilead Sciences, Merck, and ViiV/GlaxoSmithKline.
Josep M. Llibre, MD, PhD

Infectious Disease and “Fight against AIDS and Infectious Diseases Foundation”
Hospital Universitari Germans Trias i Pujol
Barcelona, Spain

Josep M. Llibre, MD, PhD, has disclosed that he has served on an advisory board or panel and as a consultant for Gilead Sciences, Janssen, MSD, and ViiV.

Program Medium

This program has been made available online.


Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Clinical Care Options (CCO) presents a woman’s perspective on managing the long-term effects of HIV, antiretroviral therapy, and aging

person default Anonymous Patient Released: January 11, 2022

Audio from Dr. Karen Ha and Clinical Care Options (CCO): Data suggest there is a role for PIs in current practice for rapid initiation and experienced patients

Karen Ha, MD Released: January 6, 2022

From Dr. Fidelia Bernice and Clinical Care Options (CCO), expert commentary on managing polypharmacy in people with HIV

Fidelia Bernice, PharmD Released: January 6, 2022

Audio from Dr. Karen Ha and Clinical Care Options (CCO): Data suggest there is a role for NNRTIs in current practice, including for patients who have experienced weight gain with INSTI-based ART

Karen Ha, MD Released: January 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings